ICICI Prudential Asset Management Co Ltd Has $9.47 Million Stock Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)

ICICI Prudential Asset Management Co Ltd lifted its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 108.0% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 28,316 shares of the medical research company’s stock after purchasing an additional 14,700 shares during the quarter. Bio-Rad Laboratories accounts for 1.0% of ICICI Prudential Asset Management Co Ltd’s investment portfolio, making the stock its 28th largest holding. ICICI Prudential Asset Management Co Ltd owned 0.10% of Bio-Rad Laboratories worth $9,474,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Janney Montgomery Scott LLC grew its holdings in Bio-Rad Laboratories by 16.8% during the first quarter. Janney Montgomery Scott LLC now owns 4,724 shares of the medical research company’s stock valued at $1,634,000 after purchasing an additional 680 shares during the period. SG Americas Securities LLC increased its position in shares of Bio-Rad Laboratories by 289.7% in the first quarter. SG Americas Securities LLC now owns 6,792 shares of the medical research company’s stock worth $2,349,000 after purchasing an additional 5,049 shares during the last quarter. US Bancorp DE raised its stake in Bio-Rad Laboratories by 13.8% in the first quarter. US Bancorp DE now owns 9,960 shares of the medical research company’s stock valued at $3,445,000 after purchasing an additional 1,209 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its position in Bio-Rad Laboratories by 15.2% during the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 941 shares of the medical research company’s stock valued at $325,000 after purchasing an additional 124 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System grew its stake in Bio-Rad Laboratories by 4.3% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 26,050 shares of the medical research company’s stock worth $9,010,000 after buying an additional 1,076 shares in the last quarter. 65.24% of the stock is owned by institutional investors.

Bio-Rad Laboratories Trading Down 0.5 %

BIO traded down $1.87 during trading on Wednesday, reaching $362.66. 29,021 shares of the company traded hands, compared to its average volume of 245,966. Bio-Rad Laboratories, Inc. has a 12-month low of $262.12 and a 12-month high of $387.99. The company has a current ratio of 6.14, a quick ratio of 4.52 and a debt-to-equity ratio of 0.16. The firm has a fifty day simple moving average of $339.68 and a 200 day simple moving average of $313.17.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.16 by $0.85. The business had revenue of $649.70 million during the quarter, compared to analyst estimates of $628.18 million. Bio-Rad Laboratories had a positive return on equity of 3.74% and a negative net margin of 30.18%. The company’s revenue for the quarter was up 2.8% on a year-over-year basis. During the same period last year, the company earned $2.33 EPS. As a group, equities analysts forecast that Bio-Rad Laboratories, Inc. will post 9.93 EPS for the current fiscal year.

Insider Activity

In other news, EVP James Barry sold 623 shares of the stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total value of $205,895.27. Following the sale, the executive vice president now owns 147 shares in the company, valued at $48,582.03. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, EVP James Barry sold 623 shares of Bio-Rad Laboratories stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total value of $205,895.27. Following the sale, the executive vice president now directly owns 147 shares in the company, valued at approximately $48,582.03. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, COO Andrew J. Last sold 3,000 shares of the business’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $329.94, for a total value of $989,820.00. Following the transaction, the chief operating officer now directly owns 7,559 shares in the company, valued at $2,494,016.46. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 17.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. StockNews.com upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Friday, November 1st. Citigroup upped their price objective on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Wells Fargo & Company initiated coverage on Bio-Rad Laboratories in a report on Tuesday, August 27th. They set an “equal weight” rating and a $340.00 price target on the stock. Finally, Royal Bank of Canada upped their price objective on shares of Bio-Rad Laboratories from $446.00 to $469.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $391.80.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.